Darnytsia Registers in Israel a Medicine for Treating and Preventing Candidiasis Infections

Darnytsia Pharmaceutical Company has registered in Israel a medicine for treating and preventing candidiasis infections.

Israel is a country with a strict regulatory system. The requirements for the quality and effectiveness of medicines here are among the highest in the world. Registration of Darnytsia medicine in this country ensures the indisputable quality, effectiveness and safety of Ukrainian medicines.

As a reminder, Darnytsia medicine for the local treatment of acute inflammatory diseases of the oral cavity and throat has been successfully registered in Moldova recently. An antibacterial medicine for the systemic treatment and prevention of infectious diseases has also been registered in Bosnia and Herzegovina. And a medicine used in the complex treatment of acute and chronic heart failure, acute and chronic renal failure, nephrotic syndrome, liver diseases and arterial hypertension has been registered in New Zealand.

In general, Darnytsia high-quality and safe medicines are already trusted in 21 countries of the world.

“More and more Darnytsia medicines are conquering new markets. Our medicines are high-quality, safe and effective. After all, Darnytsia is a modern, world-class production, which is confirmed by national and international certificates. 
In addition, we offer a wide range of medicines that can help overcome diseases, helping patients in Ukraine and the world to strengthen their health. That is why the geography of our markets is constantly expanding,” Anna Pavliuk-Havrylova, Head of the Department of International Registration and Market Expansion at Darnytsia Pharmaceutical Company, says.